Alexion has decided to scrap its experimental drug for Sanfilippo B, a devastating neurodegenerative disease.
Patients enrolled in a Phase 1/2 trial for the Sanfilippo drug, called SBC-103, will continue to receive it, but “no additional Alexion studies are planned,” the company said in its fourth quarter earnings report.
About the Author Reprints
